দেশ: আয়ার্লণ্ড
ভাষা: ইংরেজি
সূত্র: HPRA (Health Products Regulatory Authority)
Cetrimide; Chlorhexidine gluconate
GlaxoSmithKline Consumer Healthcare (Ireland) Limited
D08AJ; D08AJ04
Cetrimide; Chlorhexidine gluconate
0.5/0.1 percent weight/weight
Cream
Product not subject to medical prescription
Quaternary ammonium compounds; cetrimide
Marketed
1991-06-26
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Savlon Antiseptic Cream Cetrimide 0.5% w/w Chlorhexidine Digluconate 0.1% w/w 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active ingredients: Cetrimide 0.50% w/w Chlorhexidine digluconate 0.10% w/w Excipients: Cetostearyl alcohol 10.00% w/w Methyl parahydroxybenzoate (E218) 0.01% w/w Propyl parahydroxybenzoate (E216) 0.01% w/w For full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Cream. Smooth, white, homogenous cream with an antiseptic odour. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For prevention and management of superficial infections in skin tissue including wounds and minor burns. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION For cutaneous use. Apply the cream over the affected area after cleansing. 4.3 CONTRAINDICATIONS Hypersensitivity to chlorhexidine digluconate, cetrimide or to any of the excipient listed in section 6.1 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE For external use only. Avoid contact with the eyes, ears, mouth or other mucosa. If accidentally splashed into the eye, the open eye should be irrigated for at least 10 minutes. If symptoms persist or condition worsens, discontinue use and consult a physician. The product is incompatible with anionic substances (e.g. soap). H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ _D_ _a_ _t_ _e_ _ _ _P_ _r_ _i_ _n_ _t_ _e_ _d_ _ _ _2_ _3_ _/_ _0_ _5_ _/_ _2_ _0_ _1_ _8_ _C_ _R_ _N_ _ _ _2_ _2_ _0_ _5_ _9_ _8_ _0_ _p_ _a_ _g_ _e_ _ _ _n_ _u_ _m_ _b_ _e_ _r_ _:_ _ _ _1_ Information concern সম্পূর্ণ নথি পড়ুন